Ergoteles’s Avidity Biosciences RNAM Stock Holding History

Ergoteles’s Portfolio RNAM Stock Details RNAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-9,400	Closed	-$232K	–	1604
2021 Q2	$232K	Buy	+9,400	New	+$219K	0.01%	1203

Other funds holding RNAM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ergoteles's RNAM Position: Q3 2021 in Review

Ergoteles sold out of Avidity Biosciences (RNAM) in Q3 2021, closing a stake of 9,400 shares — an estimated $232K sold.

Ergoteles first reported a position in RNAM in Q2 2021 and held it in 1 quarter. The position peaked at $232K in Q2 2021. 111 funds tracked by Wall St. Rank hold RNAM as of Q3 2021.

Ergoteles reported no remaining Avidity Biosciences position as of Q3 2021 after selling out during the quarter.
Ergoteles sold 9,400 Avidity Biosciences shares in Q3 2021, an estimated $232K.
Ergoteles first reported a position in Avidity Biosciences in Q2 2021 and held it in 1 quarter.
Ergoteles's Avidity Biosciences position peaked at $232K in Q2 2021.
111 funds tracked by Wall St. Rank held Avidity Biosciences as of Q3 2021.

Based on Ergoteles's 13F filing for Q3 2021, filed 15 Nov 2021.